Financial services provider Silver Falcon plans to acquire biotechnology company Hemogenyx Pharmaceuticals (Hemogenyx Pharma) for £8m ($10.5m).

The transaction will enable the acquirer company to expand its business operations.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Both the acquirer and target companies are based in the UK.

Adcock Ingram Holdings has announced its 100% acquisition of Genop Holdings, a subsidiary of healthcare service provider Genop Healthcare.

The transaction complements the acquirer company’s existing portfolio.

“Adcock Ingram Holdings has announced its 100% acquisition of Genop Holdings, a subsidiary of healthcare service provider Genop Healthcare.”

Both companies involved in the acquisition are based in South Africa.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Chinese biopharmaceutical products provider Boya Bio-pharmaceutical Group (formerly Jiangxi Boya Bio-Pharmaceutical), plans to acquire 82% stake in an undisclosed Chinese pharmaceutical company.

Financial services provider China Huarong Asset Management (formerly China Huarong Asset Management), has announced the sale of eight million shares representing 1.73% stake in pharmaceutical company Northeast Pharmaceutical Group.

Both companies involved in the transaction are based in China.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact